Summit Therapeutics Inc. research snapshot
SMMT AI stock analysis currently reads Summit Therapeutics as a single-asset, late-stage oncology company whose equity value is driven by ivonescimab, a PD-1/VEGF bispecific antibody licensed from Akeso for major markets outside China. At the July 12, 2026 data cutoff, SMMT last closed at $15.25 on July 10, with an implied market capitalization of about $11.84 billion on roughly 776.16 million shares. The near-term setup centers on a U.S. BLA for EGFR-mutated second-line NSCLC with a PDUFA goal date of November 14, 2026, plus multi-regional Phase III programs against standard immuno-oncology regimens. The company remains pre-revenue, is burning cash, and has disclosed substantial going-concern language around its cash runway. This is informational research, not investment advice.
Current price
$15.25
Market cap
$11.84 billion
AI score
52 / 100
Rating
Binary late-stage oncology bet with large addressable market and high financing risk
Trend status
Volatile consolidation below the 52-week high, near short-term averages
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Summit is a clinical-stage biopharma building value around one lead molecule, ivonescimab, for non-small cell lung cancer and selected other solid tumors. There is no commercial product revenue in Summit territories yet. | High |
| Moat | Potential moat is molecular design, multi-trial clinical evidence, territorial rights outside China, and partnerships. It is not a durable commercial moat until approvals, reimbursement, and share against PD-1 standards are proven. | Medium |
| Management | Co-CEO and Chairman Bob Duggan is a majority stockholder with a track record of large biotech capital allocation (Pharmacyclics). The company is a controlled company, so governance and key-person risk are material. | Medium |
| Financial trend | Pre-revenue. FY2025 GAAP net loss was $1,079.6 million (heavily stock-compensation driven); non-GAAP net loss was $347.2 million. Q1 2026 GAAP net loss was $189.4 million with $122.3 million operating cash use. | High |
| Valuation | At $15.25, SMMT prices a large success probability into a pre-revenue pipeline company. Trailing P/E is not meaningful (negative EPS). Book value is thin relative to market cap, so valuation is almost entirely pipeline option value. | Medium |
| Technical trend | Price sits well below the 52-week high near $30.98 and near short-term moving averages, with elevated event-driven biotech volatility into the November 2026 PDUFA window. | Medium |
| Risk level | Risk is very high: regulatory decision risk, overall-survival debate, trial failures, competitive PD-1 franchise defense, cash runway, equity dilution, and single-asset concentration. | High |
| AI confidence | Facts from company filings and releases are well supported, but any multi-year price path has limited confidence because one clinical or FDA outcome can dominate the equity. | Medium |
| Investment certainty | Investment certainty is low even with abundant public data. The stock is a high-conviction clinical binary more than a steady compounder. | Low |
SMMT AI stock forecast
The SMMT AI stock forecast uses scenario ranges rather than a precise price prediction. A standard EPS and P/E three-scenario model is not useful as a price target while trailing and near-term EPS remain negative. Practical ranges instead reflect PDUFA odds, HARMONi-3 and broader Phase III outcomes, competitive positioning versus PD-1 standards, and the size and timing of equity financing.
$28 to $40
More likely if the FDA approves the HARMONi BLA on or near the November 14, 2026 PDUFA date, Western survival and safety data support a competitive label, HARMONi-3 squamous final PFS is positive in 2H 2026, and investors re-rate Summit as a multi-indication oncology franchise rather than a single-readout biotech.
$14 to $22
More likely if the stock remains an event-driven range as the market balances positive China data and a funded Phase III program against cash burn, mixed Western OS maturity, financing needs, and uncertain commercial share versus established PD-1 regimens.
$6 to $12
More likely if the FDA issues a complete response or requires more survival evidence, a key global Phase III misses, competitive data weaken the PD-1/VEGF thesis, or dilutive capital raises reset the share count before revenue arrives.
SMMT AI technical analysis
SMMT AI technical analysis is cautious and event-driven as of the July 12, 2026 cutoff. MarketBeat and Yahoo quote snapshots put the July 10 close at $15.25, with a 52-week range of about $12.55 to $30.98. Investing.com technicals near the cutoff showed RSI near 44.5, a 50-day moving average near $15.37, and a 200-day moving average near $14.63, so price is consolidating around intermediate averages after a large drawdown from the highs.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $15.25 | July 10, 2026 closing quote used for market-cap math and technical context. |
| Near support | $14.50 to $15.00 | Area around the 200-day average near $14.63 is the first visible support band. |
| Secondary support | $12.55 to $13.00 | The 52-week low area near $12.55 is the next major support if event risk hits. |
| Resistance | $16.00 to $18.00 | Short-term overhead from recent averages and prior consolidation; some snapshots placed the 50-day average higher earlier in the summer. |
| Higher resistance | $30.98 | The 52-week high is the major upside reference if PDUFA and Phase III news re-rate the stock. |
| Momentum | RSI about 44.5, neutral to soft | Momentum was neither deeply oversold nor overbought near the cutoff, so news catalysts matter more than oscillator extremes. |
| Volume | About 5.5 million average daily shares | Average volume supports active event trading, but clinical and FDA gaps can still overwhelm technical levels. |
| Volatility | Elevated biotech event volatility | PDUFA, Phase III readouts, financing, and competitor immuno-oncology data can gap price through chart levels. |
| Invalidation | Sustained close below $12.55 | A break of the 52-week low would invalidate the consolidation thesis and force a full review of clinical, regulatory, and financing assumptions. |
SMMT AI trading strategy
The SMMT AI trading strategy is a rules-based research framework for a binary, event-driven biotech. It is not personal advice and should be used with live prices, position sizing, trial calendars, FDA timelines, and independent risk limits.
Watch for SMMT to hold above $14.50 to $15.00 and reclaim the $16 to $18 zone with expanding volume and no adverse FDA, survival, or financing headlines before treating any move as a recovery trend.
A sustained close below the $14.50 band weakens the setup. A break of $12.55 should invalidate the recovery thesis and prompt a full fundamental review.
If SMMT revisits the $12.55 to $13.00 support zone without a new negative clinical or regulatory catalyst, compare the drawdown with cash position, PDUFA path, Phase III calendar, and remaining ATM capacity before considering a tactical bounce framework.
Do not treat a complete-response letter, failed primary endpoint, or emergency financing gap as ordinary technical noise. Define a hard loss limit before entry because biotech gaps can be large.
Track the November 14, 2026 PDUFA decision, HARMONi-3 squamous final PFS in 2H 2026, non-squamous HARMONi-3 timing into 1H 2027, HARMONi-7 and HARMONi-GI3 enrollment, cash and short-term investments, operating cash burn, ATM usage, and competitor PD-1/VEGF data.
Reduce confidence if cash falls below planned trial needs without a clear financing plan, if FDA feedback hardens around overall survival, or if a global Phase III misses while dilution continues.
Investment research summary
Customers of Summit products would ultimately be physicians, health systems, and payers who pay for better cancer outcomes. Today Summit is still converting clinical development into regulatory filings rather than product sales. The business essence is a license-led bet that ivonescimab can improve on or combine PD-1 and VEGF mechanisms in one molecule for NSCLC and later other solid tumors.
Possible advantages include cooperative PD-1/VEGF binding design, multi-Phase III evidence, China commercial experience under Akeso, territorial exclusivity in Summit markets, and collaboration breadth. These do not yet form a Buffett-style durable moat: Merck and other immuno-oncology leaders can defend share with data, combinations, pricing, and sales force scale.
The thesis fails if Western overall survival is insufficient for approval or broad use, if China results do not transfer to multi-regional populations, if first-line HARMONi-3 loses to pembrolizumab-based care, if competitors match the mechanism faster, or if capital markets force highly dilutive financing before launch cash flows appear.
Bob Duggan and Dr. Maky Zanganeh co-lead the company. Duggan is a majority owner and the firm is a controlled company under Nasdaq rules, which can align incentives but reduces minority-shareholder checks. Capital allocation has funded large Phase III expansion and Akeso license economics; key-person dependence and equity-based compensation noise remain important monitoring points.
Immuno-oncology remains a multi-decade category. PD-1/VEGF bispecifics sit inside a civilization-scale fight over how best to treat common cancers. Summit is attempting to move from China-validated science to Western standard-of-care disruption. That is a high-upside trend, but standards like pembrolizumab are entrenched.
At about $11.84 billion of equity value with no product revenue in Summit territories, the market is already pricing meaningful clinical and commercial success. Cash of $598.7 million at March 31, 2026 is a partial cushion, not a full margin of safety, because quarterly operating cash use was $122.3 million and going-concern language has been disclosed. Negative EPS makes classic P/E targets unreliable.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| SMMT price | $15.25 at the July 10, 2026 close | MarketBeat and Yahoo Finance quote snapshots | July 12, 2026 |
| Shares outstanding | 776.16 million | StockAnalysis and MarketWatch share statistics cross-check | July 12, 2026 |
| Market capitalization | $11.84 billion, verified as $15.25 x 776.16 million shares | financial_rigor.py verify-market-cap; matches ~$11.84B reported quotes | July 12, 2026 |
| FY2025 GAAP net loss | $1,079.6 million, or $(1.44) per share | Summit FY2025 full-year financial results press release | July 12, 2026 |
| FY2025 non-GAAP net loss | $347.2 million, or $(0.46) per share | Summit FY2025 full-year financial results press release | July 12, 2026 |
| Cash, cash equivalents, and short-term investments | $598.7 million at March 31, 2026 (down from $713.4 million at year-end 2025) | Summit Q1 2026 results; Yahoo cash figure $598.73M cross-check | July 12, 2026 |
| Q1 2026 net loss and operating cash use | GAAP net loss $189.4 million; net cash used in operations $122.3 million | Summit Q1 2026 results press release | July 12, 2026 |
| PDUFA goal date for HARMONi BLA | November 14, 2026 for ivonescimab plus chemotherapy in 2L+ EGFRm non-squamous NSCLC | Summit operational updates and Q1 2026 press release | July 12, 2026 |
| HARMONi PFS primary endpoint | PFS HR 0.52 vs placebo plus chemotherapy (p<0.00001) in global Phase III | Summit HARMONi topline results communications | July 12, 2026 |
| Valuation math | P/E not meaningful with FY2025 GAAP EPS of -$1.44; approximate P/B near 21.8x using Q1 2026 equity of $545.9 million | financial_rigor.py verify-valuation and company balance sheet | July 12, 2026 |
| Moving averages and momentum | 50-day about $15.37, 200-day about $14.63, RSI about 44.5 | Investing.com technical snapshot near cutoff | July 12, 2026 |
| Analyst consensus snapshot | Hold consensus; average 12-month target about $26.97 (range $7.70 to $45.00) | MarketBeat analyst forecast summary | July 12, 2026 |
This SMMT AI stock analysis page is an informational research tool only. It is not investment advice, financial advice, tax advice, a recommendation, or a promise of future returns. Forecast ranges are scenarios based on public filings, company press releases, quote snapshots, technical data, and third-party sources available as of July 12, 2026. They may be wrong, incomplete, or outdated after FDA decisions, clinical readouts, financing events, competitive data, cash-burn updates, market moves, or macro conditions. Clinical-stage biotechnology equities can lose most or all of their value.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
